Insulin derivatives with a terminal LPXT motif

This patent portfolio, assigned to Arri Russell Morris, relates to medical technology, and is available for sale through IPApproach.

Assignee

Arri Russell Morris

Availability

For Sale

Overview

This patent relates to novel rapid-acting insulin derivatives and physiologically tolerable salts thereof that offer a simplified and highly efficient synthesis process compared to insulin glulisine and similar analogs. The invention defines insulin derivatives in which the B-chain terminates with a Leucine-Proline-X-Threonine motif, where X may be any amino acid residue, and where both the A-chain and B-chain begin with Glycine, enabling a streamlined manufacturing pathway.

This asset represents a proprietary manufacturing modality for a rapid-acting insulin analog that is structurally distinct from Insulin Glulisine (Sanofi) by two amino acid residues. This structural distinction provides the acquirer with a dual strategic advantage:

1- New Composition IP – The resulting molecule qualifies as a biobetter, not a biosimilar, making it eligible for independent patent protection and market exclusivity.

2- Defensive Blocking – Acquisition prevents generic competitors from leveraging the high-efficiency "Sortase Two-Cut" manufacturing pathway to introduce a disruptive low-cost alternative.

Overall, the portfolio offers strategic value for pharmaceutical companies seeking manufacturing efficiency, lifecycle extension, biosimilar defense, and next-generation insulin differentiation in a highly competitive global diabetes market.

Listing updated August 21, 2026

IPApproach lists patents and portfolios where the seller has not requested anonymity or confidentiality. Patent numbers link to public records on Google Patents.